MTaI Seeks Streamlining Of Taxes And Duties To Make Medical Devices Affordable
Medical Technology Association of India (MTaI), today said the government should streamline tax and duty structure in Union Budget 2019-20 to ensure people get long-term access to quality medical devices.
Read More
Acceptance of eIFU for Medical Device a Welcome Move: MTaI
Medical Technology Association of India (MTaI), which represents leading research-based medical technology companies with significant investments in India, today welcomed the Ministry of Health & Family Welfare Gazette notification on acceptance
Read More
Inclusion of medical device industry in DTAB panel on compensation a step in right direction, says MTaI
MTaI welcomed the DTAB sub-committee to examine compensation norms under MDR 2017, calling industry inclusion a positive step toward a balanced.
Read More
Overview of 2018 for med-tech and expectations for 2019
India’s MedTech sector is a sunrise industry, expected to grow from $6.3 bn to $9.5 bn in four years: Pavan Choudary.
Read More
Increase in stent prices shows govt’s commitment to quality healthcare: MTaI
MTaI says NPPA’s 4.2% stent price hike aligns with inflation, supports industry viability, and signals govt’s commitment to quality healthcare.
Read More
MTaI welcomes government’s decision to create NMDPC
MTaI backs NMDPC, urging fair Make-in-India opportunities so global firms can invest, boost FDI, and expand quality medical device access for Indian patients.
Read More
MTaI seeks one time increase of 18% in MRP of medical device
MTaI urges govt to allow a one-time 18% MRP hike on medical devices to offset rupee depreciation, inflation, and ensure uninterrupted supply.
Read More
AN IDEAL ROADMAP TO STRENGTHEN MEDTECH IN INDIA
India’s medtech needs a clear roadmap—separate from drugs, nuanced regulation, R&D incentives, export focus, and smart pricing—to unlock Ayushman Bharat’s poten
Read More
Create A Level-Playing Field For Importers Vis-à-Vis Local Manufacturers
NPPA data shows hospitals—not device makers—drive high costs. Trade Margin Rationalization should be PTT-based; cost-based models distort markets and innovation
Read More